PDGFB and central nervous system cancer: Although our analysis did not reach statistical significance due to the small sample size of mice (n = 5) injected with the RCAS-PDGFB + shGL2 vector who developed brain tumor symptoms before the endpoint of the study, there was a clear trend toward glioma formation upon CSMD1 knockdown.